Compare AbbVie Inc (ABBV) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? AbbVie Inc trades at $254.11 (market cap $449.91B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.77. The key difference: AbbVie Inc pays a 2.72% dividend while Roundhill S&P 500 0DTE Covered Call Strategy ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | XDTE | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $261.07 | $44.76 |
52-Week Low | $184.85 | $36.00 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
XDTE trades at $39.16, up 0.8% with a bearish technical signal from moving averages. The ETF generates weekly dividend income through covered call strategies on S&P 500 options, though recent analysis highlights NAV erosion concerns despite high yields. Support levels cluster around $38-39 with resistance at $39-40, indicating tight trading range constraints.
The fund's 20%+ dividend yield attracts income investors but faces structural risks from option strategy decay during market shifts. Analyst consensus remains cautious due to NAV performance lagging underlying index gains, requiring careful monitoring of distribution sustainability versus capital preservation trade-offs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
